Sirma’s MPI2 product is featured this week at the American Speech and Hearing Association (ASHA) 2018 conference.
MPI2 stuttering treatment was developed by Sirma in collaboration with the University of California, Santa Barbara Department of Speech and Hearing Sciences, and is the only stuttering treatment that has been validated by an FDA clinical trial.
MPI2 uses cutting-edge bio-feedback mechanisms, implemented as mobile apps, which train people who stutter to modify their speech behavior by identifying short phonetic intervals. MPI2 is in discussion with clinicians from the New York department of education, who employ over 9,000 speech-language pathologists, and will be offering no-cost licenses of the application to public school high-school students in 2019.
